According to TipRanks.com, Gonsalves is ranked #356 out of 7474 analysts. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Knight Therapeutics with a $6.42 average price target. Based on Knight Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $55.19 million and net profit of $8.23 million. In comparison, last year the company earned revenue of $37.27 million and had a GAAP net loss of $6.67 million. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.